Axsome's AXS-05 shows strong efficacy in treating Alzheimer's Disease Agitation, with significant CMAI score reductions.

Vadodara: Alembic Global Holding SA, a wholly owned subsidiary of Alembic Pharmaceuticals Limited has incorporated a wholly-owned subsidiary in USA, named Alembic Lifesciences Inc.

The EC has approved Otsuka Pharmaceutical and Lundbeck’s atypical oral antipsychotic, Rxulti (brexpiprazole), for treating ...

The European Commission (EC) has approved Danish CNS specialist Lundbeck (LUND: CO) and Otsuka Europe’s Rxulti ...

Otsuka Pharmaceutical Europe and Lundbeck have announced that the European Commission has approved Rxulti (brexpiprazole) for ...

Otsuka Pharmaceutical Europe Ltd. (Otsuka) and H. Lundbeck A/S (Lundbeck) today announced that the European Commission (EC) has approved Rxulti® (brexpiprazole) for the treatment of schizophrenia in ...

Age at menopause may interact with factors related to the health of synapses, or nerve cell connections, to influence the risk of Alzheimer’s disease in women, a study found. Associations between ...

New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has granted approval to Hetero Labs for conducting a bioequivalence study (BE) of ...

In the AD agitation market, AXS-05 is expected to compete with brexpiprazole, the only FDA-approved treatment for this indication. However, AXS-05's potentially superior safety profile ...